### Cytarabine

#### Indication
- **Acute myeloid leukaemia with recurrent genetic abnormalities**

#### ATC codes:
- L01BC01
- EMLc

#### Indication
- **Acute myeloid leukaemia with recurrent genetic abnormalities**

#### ICD11 code:
- 2B30.0

#### INN
- **Cytarabine**

#### Medicine type
- **Chemical agent**

#### List type
- **Complementary**

#### Formulations
- **Parenteral > General injections > unspecified:**
  - 100 mg in vial powder for injection
  - 100 mg per mL in vial

#### EML status history
- **First added in 1979 (TRS 641)**
- **Changed in 2015 (TRS 994)**
- **Changed in 2019 (TRS 1021)**
- **Changed in 2023 (TRS 1049)**

#### Sex
- **All**

#### Age
- **Also recommended for children**

#### Therapeutic alternatives
- The recommendation is for this specific medicine

#### Patent information
- Patents have expired in most jurisdictions
- Read more about patents.

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of cytarabine (100 mg/mL in vial) to the EML and EMLc.